Fig. 4.

RCDCs for anti-hepatitis B surface antigen titres in sera obtained at 6 and 18 weeks of age from infants in Groups A and B

DTaP–IPV//PRP~T, diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae type-b conjugate; RCDC, reverse cumulative distribution curve.

^a Group A received the DTaP–IPV//PRP~T combination vaccine at 6, 10, 14 weeks of age and the recombinant hepatitis B vaccine at 0, 6 and 14 weeks of age.

^b Group B received the DTaP–IPV//PRP~T vaccine and the recombinant hepatitis B vaccine at 6, 10 and 14 weeks of age.